Clinical Trials Logo
  1. Home
  2. Adenomatous Polyposis Coli
  3. NCT02113202

Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW — FLUOFAP  

Adenomatous Polyposis Coli Clinical Trial

Official title:
Visualization of a VEGF-targeted Near-Infrared Fluorescent Tracer in Patients With Familial Adenomatous Polyposis During Fluorescence Endoscopy A Single Center Pilot Intervention Study

Clinical Trial Summary

There is a need for better visualization of polyps during surveillance endoscopy in patients with hereditary colon cancer syndromes like Familial Adenomatous Polyposis (FAP) and Lynch Syndrome (LS), to improve the adenoma detection rate. Optical molecular imaging of adenoma associated biomarkers is a promising technique to accommodate this need. The biomarker Vascular Endothelial Growth Factor (VEGF) is overexpressed in adenomatous colon tissue versus normal tissue and has proven to be a valid target for molecular imaging. The University Medical Center Groningen (UMCG) developed a fluorescent tracer by labeling the VEGF-targeting humanized monoclonal antibody bevacizumab, currently used in anti-cancer therapy, with the fluorescent dye IRDye800CW. The investigators hypothesize that when bevacizumab-IRDye800CW is administered to patients, it accumulates in VEGF expressing adenomas, enabling adenoma visualization using a newly developed near-infrared (NIR) fluorescence endoscopy platform (NL43407.042.13). This hypothesis will be tested in this feasibility study, next to the determination of the optimal tracer dose.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02113202
Study type Interventional
Source University Medical Center Groningen
Contact
Status Completed
Phase Phase 1
Start date March 2014
Completion date October 2015
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00585312 - Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Completed NCT03095703 - Sirolimus and Familial Adenomatous Polyposis (FAP) Phase 2
Completed NCT03649971 - A Study of Guselkumab in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT05014360 - A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT01604564 - Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT03027401 - Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Terminated NCT00140894 - A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Phase 4
Active, not recruiting NCT01187901 - A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Phase 2
Recruiting NCT00319007 - Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Phase 2
No longer available NCT04948398 - Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis